5 Results

People

  1. Tallman
    Tallman
  2. Adel
    Adel
  3. DeBlasio
    DeBlasio
  4. Douer
    Douer
  5. Jurcic
    Jurcic
  6. Nimer
    Nimer
  7. Park
    Park
  8. Akin
    Akin
  9. Berman
    Berman
  10. Chaim
    Chaim

Groups

  1. Adult Leukemia (5)
  2. Center for Hematologic Malignancies (5)
  3. Department of Medicine (5)
  4. Hematologic Malignancies, Division of (5)
  5. Epidemiology and Biostatistics (2)
  6. Biostatistics Service (1)
  7. Body Imaging Service (1)
  8. Executive Committee, Center for Hematologic Malignancies (1)
  9. GSK Faculty (1)
  10. Human Oncology and Pathogenesis Program (1)
  1. "Nelly Adel"
  2. "Martin Tallman"
Formats
  1. Meeting Abstract (4)
  2. Journal Article (1)
Groups
  1. Adult Leukemia (5)
  2. Center for Hematologic Malignancies (5)
  3. Department of Medicine (5)
  4. Hematologic Malignancies, Division of (5)
  5. Epidemiology and Biostatistics (2)
  6. Biostatistics Service (1)

More Groups

People
  1. Martin Tallman (5)
  2. Nelly Adel (5)
  3. Dan Douer (2)
  4. Jae Park (2)
  5. Joseph Jurcic (2)
  6. Stephen Nimer (2)

More People

Years
  1. 2014 (1)
  2. 2013 (2)
  3. 2011 (2)
Publications
  1. Blood (3)
  2. Journal of Clinical Oncology (1)
  3. Leukemia Research (1)
Publishers
  1. American Society of Hematology (3)
  2. American Society of Clinical Oncology (1)
  3. Elsevier Ltd (1)

Results (5)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia
    Meeting Abstract

    Seddon, A. N.; Michael, A. G.; Adel, N. G.; Tallman, M. S.; Akin, O.; Chaim, J.; Drill, E.
    Blood (2014)

    Fulltext@MSK | Save
  • High-dose cytarabine monotherapy versus intermediate or high-dose cytarabine in combination with other agents as second-line salvage therapy In patients with acute myeloid leukemia who did not respond to initial induction therapy
    Meeting Abstract

    Dang, T. O. T.; Hilden, P.; Devlin, S. M.; Rampal, R. K.; Levine, R. L.; Berman, E.; Klimek, V. M.; Adel, N. G.; Tallman, M. S.
    Blood (2013)

    Fulltext@MSK | Save
  • Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death
    Journal Article

    Altman, J. K.; Rademaker, A.; Cull, E.; Weitner, B. B.; Ofran, Y.; Rosenblat, T. L.; Haidau, A.; Park, J. H.; Ram, S. L.; Orsini, J. M.; more...
    Leukemia Research (2013)

    Fulltext@MSK | Save
  • Decitabine for the treatment of acute myeloid leukemia (AML): Memorial Sloan-Kettering Cancer Center experience
    Meeting Abstract

    Ganetsky, A.; Adel, N. G.; Frattini, M. G.; Maslak, P. G.; Heaney, M. L.; Jurcic, J. G.; Tallman, M. S.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Administration of all-trans retinoic acid (ATRA) to newly diagnosed patients (pts) with acute promyelocytic leukemia (APL) is delayed even at experienced centers and associated with an increased early death rate (EDR): A retrospective analysis of 205 pts
    Meeting Abstract

    Altman, J. K.; Rademaker, A.; Cull, E.; Weitner, B. B.; Ofran, Y.; Rosenblat, T. L.; Haidau, A.; Park, J. H.; Ram, S.; Orsini, J.; more...
    Blood (2011)

    Fulltext@MSK | Save